Development of controlled-release cisplatin dry powders for inhalation against lung cancers

Levet, Vincent; Rosière, Rémi; Merlos, Romain; Fusaro, Luca; Berger, Gilles; Amighi, Karim; Wauthoz, Nathalie

doi:10.1016/j.ijpharm.2016.10.019

Cited by 47 publications

(36 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we have chosen to illustrate one development of a dry powder for inhalation that has almost all of the different aspects required to render it technically and clinically applicable (i.e. potentially well-tolerated excipients, a high drug loading and FPF, and using industrial scaling-up techniques with a good production yield) [101][102][103].…”

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

“…This development has consisted of reducing CIS microcrystals to submicron crystals (800 nm) by high-pressure homogenization and then embedding them into a highly lipophilic matrix of tristearin (TS) using spray drying to control the particle size and the release of CIS. Tocopheryl PEG1000 succinate (TPGS) is at the surface of particles to decrease the impact of the non-absorptive clearance systems [101]. High-pressure homogenization and spray-drying are both easily scalable techniques.…”

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

“…45-61%). However, the dry powder production and its characterization have required the use of highly specific procedures and infrastructure to protect the manipulator and the environment, as described in Wauthoz et al and Levet et al [101,104]. TS and TPGS are excipients that are not yet authorized for inhalation.…”

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

“…Moreover, the increase from 25% to 50% of TS in the matrix significantly decreases the CIS release and the burst effect, but with the same CIS release percentage after 24 h (~80%). Moreover, the addition of 0.5% TPGS at the microparticle surface modifies the release profile from microparticles containing 50% TS lipid matrix by increasing the burst effect (20% vs 11% after 2 min) but decreasing the CIS release (44% vs 63% after 6 h and 55% vs 79% after 24 h) [101]. The formulation presenting controlled release properties and an acceptable drug loading (i.e.…”

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

See 3 more Smart Citations

Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects

Wauthoz

Rosière

Amighi

2020

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

Introduction: Since 1968, inhaled chemotherapy has been evaluated and has shown promising results up to phase II but has not yet reached the market. This is due to technological and clinical challenges that require to be overcome with the aim of optimizing the efficacy and the tolerance of drug to reopen new developments in this field. Moreover, recent changes in the therapeutic standard of care for treating the patient with lung cancer also open new opportunities to combine inhaled chemotherapy with standard treatments. Areas covered: Clinical and technological concerns are highlighted from the reported clinical trials made with inhaled cytotoxic chemotherapies. This work then focuses on new pharmaceutical developments using dry powder inhalers as inhalation devices and on formulation strategies based on controlled drug release and with sustained lung retention or based on nanomedicine. Finally, new clinical strategies are described in regard to the impact of the immunotherapy on the patient's standard of care. Expert opinion: The choice of the drug, inhalation device, and formulation strategy as well as the position of inhaled chemotherapy in the patient's clinical care are crucial factors in optimizing local tolerance and efficacy as well as in its scalability and applicability in clinical practice.

show abstract

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

Section: Controlled-release Formulations With Sustained Lung Retentiomentioning

confidence: 99%

See 2 more Smart Citations

Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects

Wauthoz

Rosière

Amighi

2020

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, the factors affecting the ultrasonic nebulizers are different as the equipment works on different principles: the temperature of the piezoelectric crystal, the time of nebulization, the addition of buffer, pH and the drug principles [57][58][59][60][61][62]. Dry powder cisplatin has been created and it could be possibly administered as local therapy [63][64][65]. Dry powder has the disadvantage that the particles have two different axis (x,y) and one axis is always larger so they can easily induce cough.…”

Section: Factors Affecting the Production And Depositionmentioning

confidence: 99%

Inhaled chemotherapy adverse effects: mechanisms and protection methods

et al. 2019

View full text Add to dashboard Cite

Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them.

show abstract